Quality of Life Research

, Volume 16, Issue 6, pp 929–937 | Cite as

Predicting quality of life impairment in chronic schizophrenia from cognitive variables

Original Paper


Background The aim of this study was to see whether and how cognition deficit predicts quality of life impairments in schizophrenia patients. Method The Computerized Cambridge Automated Neuropsychological Test Battery, the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and the Quality of Life Scale (QLS) were used to assess 62 patients with chronic schizophrenia. Step-wise multiple regression analysis was used in order to determine cognitive variables that would predict the scores of each Q-LES-Q and QLS domain scores. Results Regression analysis revealed a significant association of the cognitive deficits with both general and domain-specific quality of life impairment measured with Q-LES-Q and QLS. Deficits in executive functions, visual sustained attention, memory and motor skills have been found to be valid predictors both before and after controlling for the severity of symptoms, emotional distress, side effects, age, education, and illness duration. Conclusions This study suggests that deficits in executive functioning, attention, memory and motor skills substantially contributes to predicting impairments across a wide range of HRQL domains, and, consequently, to quality of life appraisal in schizophrenia. Cognitive predictors cannot be attributed to illness-related and background variables. It can be concluded that, when aiming at the improvement of quality of life in schizophrenia patients, cognitive functioning should be targeted.


Schizophrenia Quality of life Neurocognitive functioning Predicting 


  1. 1.
    Testa, M. A., & Simonson, D. C. (1996). Assessment of quality-of-life outcomes. The New England Journal of Medicine, 334, 835–840.PubMedCrossRefGoogle Scholar
  2. 2.
    Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA, 273, 59–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Ritsner, M. S. (2007). The distress/protection vulnerability model of the quality of life impairment syndrome: Current evidence and new directions for research. In M. S. Ritsner & A. G. Awad (Eds.), Quality of life impairment in Schizophrenia, mood and anxiety disorders. New perspectives on research and treatment (pp. 3–19). Springer.Google Scholar
  4. 4.
    Keefe, R. S., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J. M., Adler, L. W., Manschreck, T. C., Swartz, M., Rosenheck, R., Perkins, D. O., Walker, T. M., Stroup, T. S., McEvoy, J. P., & Lieberman, J. A. (2006). Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology, 31, 2033–2046.PubMedCrossRefGoogle Scholar
  5. 5.
    Heslegrave, R. J., Awad, A. G., & Voruganti, L. N. (1997). The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. Journal of Psychiatry and Neuroscience, 22, 235–243.PubMedGoogle Scholar
  6. 6.
    Addington, J., & Addington, D. (2002). Cognitive functioning in first-episode schizophrenia. Journal of Psychiatry and Neuroscience, 27, 188–192.PubMedGoogle Scholar
  7. 7.
    Kaiser, W. (2000). Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life. British Journal of Psychiatry, 176, 92–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Aksaray, G., Oflu, S., Kaptanoglu, C., & Bal, C. (2002). Neurocognitive deficits and quality of life in outpatients with schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry, 26, 1217–1219.CrossRefGoogle Scholar
  9. 9.
    Sota, T. L., & Heinrichs, R. W. (2004). Demographic, clinical, and neurocognitive predictors of quality of life in schizophrenia patients receiving conventional neuroleptics. Comprehensive Psychiatry, 45, 415–421.PubMedCrossRefGoogle Scholar
  10. 10.
    Alptekin, K., Akvardar, Y., Kivircik Akdede, B. B., et al. (2005). Is quality of life associated with cognitive impairment in schizophrenia?. Progress in Neuro-psychopharmacology and Biological Psychiatry, 29, 239–244.PubMedCrossRefGoogle Scholar
  11. 11.
    Wegener, S., Redoblado-Hodge, M. A., Lucas, S., et al. (2005). Relative contributions of psychiatric symptoms and neuropsychological functioning to quality of life in first-episode psychosis. The Australian and New Zealand Journal of Psychiatry, 39, 487–492.PubMedCrossRefGoogle Scholar
  12. 12.
    Awad, A. G., Voruganti, L. N., & Heslegrave, R. J. A. (1997). Conceptual model of quality of life in schizophrenia: Description and preliminary drugs, relationships to objective psychopathology, quality of life, clinical validation. Quality of Life Research, 6, 21–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Ritsner, M., Modai, I., Endicott, J., Rivkin, O., Nechamkin, Y., Barak, P., Goldin, V., & Ponizovsky, A. (2000). Differences in quality of life domains, psychopathological and psychosocial factors in psychiatric patients. Journal of Clinical Psychiatry, 61, 880–889.PubMedCrossRefGoogle Scholar
  14. 14.
    Ritsner, M., Gibel, A., & Ratner, Y. (2006). Determinants of changes in perceived quality of life in the course of Schizophrenia. Quality of Life Research, 15, 515–526.PubMedCrossRefGoogle Scholar
  15. 15.
    Fitzgerald, P. B., Williams, C. L., Corteling, N., et al. (2001). Subject and observer-rated quality of life in schizophrenia. Acta Psychiatrica Scandinavica, 103, 387–392 .PubMedCrossRefGoogle Scholar
  16. 16.
    Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984). The Quality of Life Scale: An instrument for rating the schizophrenic deficit scale. Schizophrenia Bulletin, 10, 388–398.PubMedGoogle Scholar
  17. 17.
    American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders. Washington, DC.Google Scholar
  18. 18.
    Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of life enjoyment and satisfaction questionnaire: A new measure. Psychopharmacology Bulletin, 29, 321–326.PubMedGoogle Scholar
  19. 19.
    Ritsner, M., Modai, I., Kurs, R., et al. (2002). Subjective quality of life measurements in severe mental health patients: Measuring quality of life of psychiatric patients: Comparison two questionnaires. Quality Life Research, 11, 553–561.CrossRefGoogle Scholar
  20. 20.
    Sahakian, B. J., & Owen, A. M. (1992). Computerized assessment in neuropsychiatry using CANTAB: Discussion paper. Journal of the Royal Society of Medicine, 85, 399–402.PubMedGoogle Scholar
  21. 21.
    Robbins, T. W., James, M., Owen, A. M., Sahakian, B. J., McInnes, L., & Rabbitt, P. (1994). Cambridge Neuropsychological Test Automated Battery (CANTAB): A factor analytic study of a large sample of normal elderly volunteers. Dementia, 5, 266–281.PubMedCrossRefGoogle Scholar
  22. 22.
    Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.PubMedGoogle Scholar
  23. 23.
    Ritsner, M., Rabinowitz, J., & Slyuzberg, M. (1995). The Talbieh Brief Distress Inventory: A brief instrument to measure psychological distress among immigrants. Comprehensive Psychiatry, 36, 448–453.PubMedCrossRefGoogle Scholar
  24. 24.
    Chouinard, G., Ross-Chouinard, A., Annale, L., et al. (1980). Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences, 7, 233.Google Scholar
  25. 25.
    White, L., Harvey, P. D., Opler, L., Lindenmayer, J. P. & PANSS Study Group. (1997). Empirical assessment of the factorial structure of clinical symptoms in Schizophrenia. Psychopathology, 30, 263–274.Google Scholar
  26. 26.
    Ritsner, M., Modai, I., & Ponizovsky, A. (2002). The Talbieh brief distress inventory: Validation for use with psychiatric patients. Comprehensive Psychiatry, 2, 144–163.Google Scholar
  27. 27.
    Hintze, J. L., NCSS & PASS. (2001). Statistical system for Windows. User’s guide. number cruncher statistical systems, number cruncher statistical systems, Kaysville. Utah. www.NCSS.com.Google Scholar
  28. 28.
    Awad, A. G., & Voruganti, L. N. (2004). Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs, 18, 877–893.PubMedCrossRefGoogle Scholar
  29. 29.
    Lambert, M., & Naber, D. (2004). Current issues in schizophrenia: Overview of patient acceptability, functioning capacity and quality of life. CNS Drugs, 2 (18 Suppl), 5–17.CrossRefGoogle Scholar
  30. 30.
    Ritsner, M., & Kurs, R. (2006). Quality-of-life impairment in severe mental illness: Focus on Schizoaffective disorders. In William H. Murray (ed.), Schizoaffective disorder: New research. (pp. 69–107). NY: NOVA Publishers.Google Scholar
  31. 31.
    Erlenmeyer-Kimling, L., Rock, D., Roberts, S. A., Janal, M., Kestenbaum, C., Cornblatt, B., & Adamo, U. H. (2000). Gottesman II. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: The New York High-Risk Project. The American Journal of Psychiatry, 157, 1416–1422.PubMedCrossRefGoogle Scholar
  32. 32.
    Zalla, T., Joyce, C., Szoke, A., Schurhoff, F., Pillon, B., Komano, O., Perez-Diaz, F., Bellivier, F., Alter, C., Dubois, B., Rouillon, F., Houde, O'., & Leboyer, M. (2004). Executive dysfunctions as potential markers of familial vulnerability to bipolar disorder and schizophrenia. Psychiatry Research, 21, 207–217.CrossRefGoogle Scholar
  33. 33.
    Hoff, A. L., Svetina, C., Maurizio, A. M., Crow, T. J., Spokes, K., & DeLisi, L. E. (2005). Familial cognitive deficits in schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 133, 43–49.CrossRefGoogle Scholar
  34. 34.
    Saperstein, A. M., Fuller, R. L., Avila, M. T., Adami, H., McMahon, R. P., Thaker, G. K., & Gold, J. M. (2006). Spatial working memory as a cognitive endophenotype of schizophrenia: Assessing risk for pathophysiological dysfunction. Schizophrenia Bulletin, 32, 498–506.PubMedCrossRefGoogle Scholar
  35. 35.
    Chen, W. J., & Faraone, S. V. (2000). Sustained attention deficits as markers of genetic susceptibility to schizophrenia. American Journal of Medical Genetics, 97, 52–57.PubMedCrossRefGoogle Scholar
  36. 36.
    Liu, S. K., Chiu, C. H., Chang, C. J., Hwang, T. J., Hwu, H. G., & Chen, W. J. (2002). Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-dependent markers. The American Journal of Psychiatry, 159, 975–982.PubMedCrossRefGoogle Scholar
  37. 37.
    Bozikas, V. P., Andreou, C., Giannakou, M., Tonia, T., Anezoulaki, D., Karavatos, A., Fokas, K., & Kosmidis, M. H. (2005). Deficits in sustained attention in schizophrenia but not in bipolar disorder. Schizophrenia Research, 78, 225–233.PubMedCrossRefGoogle Scholar
  38. 38.
    Stone, W. S., Faraone, S. V., Seidman, L. J., et al. (2001). Concurrent validation of schizotaxia: A pilot study. Biological Psychiatry, 50, 434–440.PubMedCrossRefGoogle Scholar
  39. 39.
    Tsuang, M. T., Stone, W. S., Gamma, F., & Faraone, S. V. (2003). Schizotaxia: Current status and future directions. Current Psychiatry Reports, 5, 128–134.PubMedCrossRefGoogle Scholar
  40. 40.
    Erickson, D. H., Beiser, M., Iacono, W. G., et al. (1989). The role of social relationships in the course of first-episode schizophrenia and affective psychosis. The American Journal of Psychiatry, 146, 1456–1461.PubMedGoogle Scholar
  41. 41.
    Bechdolf, A., Pukrop, R., Kohn, D., et al. (2005). Subjective quality of life in subjects at risk for a first episode of psychosis: A comparison with first episode schizophrenia patients and healthy controls. Schizophrenia Research, 79, 137–143.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  1. 1.The Rappaport Faculty of MedicineTechnion––Israel Institute of TechnologyHaifaIsrael
  2. 2.Acute Department/Research Laboratory, Technion-Faculty of MedicineSha’ar Menashe Mental Health CenterHaderaIsrael

Personalised recommendations